CSL Plasma to roll out Haemonetics NexSys PCS devices across U.S. centers by end‑2027
Haemonetics announced that CSL Plasma will deploy its NexSys PCS plasmapheresis systems and disposables at all U.S. collection centers, with the rollout slated for completion by the end of 2027. The agreement, first disclosed in August 2026, is non‑exclusive and does not include a minimum volume commitment. The news sent Haemonetics shares sharply higher, with pre‑market gains of 12‑17% and the stock reaching a 52‑week high.
Why it matters
The company said it will not revise its fiscal 2027 guidance yet, but the expanded CSL rollout could add a large source of recurring disposable revenue. Analysts responded by raising price targets, e.g., BTIG to $130 and Citi to $123.
Key facts
- 1CSL Plasma plans to complete the rollout of Haemonetics' NexSys PCS devices across all U.S. centers by the end of 2027. ibtimes.com.au
- 2The supply agreement was first announced on August 18, 2026 and is non‑exclusive with no disclosed minimum volume. ibtimes.com.au
- 3Haemonetics shares rose approximately 14% in pre‑market trading after the announcement. gurufocus.com
- 4Shares later surged 15.52% to $117.50 in early trading, touching a 52‑week high of $125.30. ibtimes.com.au
- 5Haemonetics did not change its fiscal 2027 financial guidance following the update. ibtimes.com.au
- 6BTIG raised its price target for Haemonetics to $130 from $110. investing.com
Open questions
- Exact timing of each center’s conversion remains subject to change.
Summary written by AlphAI from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.